Therapeutic action and underlying mechanisms of a combination of two pentacyclic triterpenes, aand Β-amyrin, in a mouse model of colitis

British Journal of Pharmacology

Volumn 157, Issue 6, 2009, Pages 1034-1044

  Vitor, C E ^a   Figueiredo, C P ^a   Hara, D B ^a   Bento, A F ^a   Mazzuco, T L ^a   Calixto, J B ^a  

^a FEDERAL UNIVERSITY OF SANTA CATARINA   (Brazil)

Author keywords

, amyrin; CAMP response element binding protein; Cyclooxygenase 2; Inflammation; Inflammatory bowel disease; Interleukins; Mouse colitis; Nuclear factor kB; Vascular endothelial growth factor

Indexed keywords

ALPHA AMYRIN; ALPHA AMYRIN PLUS BETA AMYRIN; BETA AMYRIN; CYCLIC AMP RESPONSIVE ELEMENT BINDING PROTEIN; CYCLOOXYGENASE 2; DEXAMETHASONE; INTERLEUKIN 10; INTERLEUKIN 1BETA; MYELOPEROXIDASE; PHOSPHOPROTEIN; TRANSCRIPTION FACTOR RELA; TRINITROBENZENESULFONIC ACID; UNCLASSIFIED DRUG; VASCULOTROPIN;

ACUTE TOXICITY; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; ARTICLE; COLITIS; COLON INJURY; CONTROLLED STUDY; CYTOKINE PRODUCTION; DOSE RESPONSE; DRUG MECHANISM; DRUG SAFETY; ENZYME ACTIVITY; MALE; MEDIATOR RELEASE; MOUSE; NEUTROPHIL CHEMOTAXIS; NONHUMAN; POLYMORPHONUCLEAR CELL; PRIORITY JOURNAL; TIME;

ANIMALS; COLITIS; DISEASE MODELS, ANIMAL; DRUG THERAPY, COMBINATION; MALE; MICE; OLEANOLIC ACID; PENTACYCLIC TRITERPENES; TRINITROBENZENESULFONIC ACID;

EID: 70350339816     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1111/j.1476-5381.2009.00271.x     Document Type: Article

References (41)

1. Alexander SP, Mathie A, Peters JA (2008). Guide to Receptors and Channels (GRAC), 3rd edn. Br J Pharmacol 153 (Suppl. 2): S1-S209.
2. Bento AF, Leite DF, Claudino RF, Hara DB, Leal PC, Calixto JB (2008). The selective nonpeptide CXCR2 antagonist SB225002 ameliorates acute experimental colitis in mice. J Leukoc Biol 84: 1213-1221.
3. Calixto JB, Otuki MF, Santos AR (2003). Anti-inflammatory compounds of plant origin. Part I. Action on arachidonic acid pathway, nitric oxide and nuclear factor kappa B NF-kappaB). Planta Med 69: 973-983.
4. Calixto JB, Campos MM, Otuki MF, Santos AR (2004). Anti-inflammatory compounds of plant origin. Part II. modulation of pro-inflammatory cytokines, chemokines and adhesion molecules. Planta Med 70: 93-103.
5. Corrêa P (1984). Dicionário de plantas úteis do Brasil e das Exóticas cultivadas. Imprensa Nacional: Rio de Janeiro.
6. Danese S, Sans M, de la Motte C, Graziani C, West G, Phillips MH et al. (2006). Angiogenesis as a novel component of inflammatory bowel disease pathogenesis. Gastroenterology 130: 2060-2073. (Pubitemid 43816964)
7. Davidson NJ, Fort MM, Muller W, Leach MW, Rennick DM (2000). Chronic colitis in IL-10-/-mice: insufficient counter regulation of a Th1 response. Int Rev Immunol 19: 91-121.
8. De Young LM, Kheifets JB, Ballaron SJ, Young JM (1989). Edema and cell infiltration in the phorbol ester-treated mouse ear are temporally separate and can be differentially modulated by pharmaco-logic agents. Agents Actions 26: 335-341.
9. Fiorucci S, Orlandi S, Mencarelli A, Caliendo G, Santagada V, Distrutti E et al. (2007). Enhanced activity of a hydrogen sulphide-releasing derivative of mesalamine (ATB-429) in a mouse model of colitis. Br J Pharmacol 150: 996-1002.
10. Ghosh S, Karin M (2002). Missing pieces in the NF-kappaB puzzle. Cell 109 (Suppl.) S81-S96.
11. Hara DB, Fernandes ES, Campos MM, Calixto JB (2007). Pharmacological and biochemical characterization of bradykinin B(2) receptors in the mouse colon: influence of the TNBS-induced colitis. Regul Pept 141: 25-34.
12. Hara DB, Leite DF, Fernandes ES, Passos GF, Guimaraes AO, Pesquero JB et al. (2008). The relevance of kinin B1 receptor upregulation in a mouse model of colitis. Br J Pharmacol 154: 1276-1286.
13. Kweifio-Okai G, Bird D, Eu P, Carroll AR, Ambrose R, Field B (1994). Effect of alpha-amyrin palmitate on adjuvant arthritis. Drugs Exp Clin Res 20: 1-5.
14. McCafferty DM, Sihota E, Muscara M, Wallace JL, Sharkey KA, Kubes P (2000). Spontaneously developing chronic colitis in IL-10/iNOS double-deficient mice. Am J Physiol Gastrointest Liver Physiol 279: G90-G99.
15. McGuckin MA, Eri R, Simms LA, Florin TH, Radford-Smith G (2008). Intestinal barrier dysfunction in inflammatory bowel diseases. Inflamm Bowel Dis 15: 100-113.
16. Martin RA, Villegas I, La Casa C, & Alarcon de la Lastra, C (2003). The cyclo-oxygenase-2 inhibitor, rofecoxib, attenuates mucosal damage due to colitis induced by trinitrobenzene sulphonic acid in rats. Eur J Pharmacol 481: 281-291.
17. Medeiros R, Otuki MF, Avellar MC, Calixto JB (2007). Mechanisms underlying the inhibitory actions of the pentacyclic triterpene alpha-amyrin in the mouse skin inflammation induced by phorbol ester 12-O-tetradecanoylphorbol- 13-acetate. Eur J Pharmacol 559: 227-235.
18. Morris GP, Beck PL, Herridge MS, Depew WT, Szewczuk MR, Wallace JL (1989). Hapten-induced model of chronic inflammation and ulceration in the rat colon. Gastroenterology 96: 795-803.
19. Neurath MF, Pettersson S (1997). Predominant role of NF-kappa B p65 in the pathogenesis of chronic intestinal inflammation. Immunobi-ology 198: 91-98.
20. Neurath MF, Fuss I, Kelsall BL, Stuber E, Strober W (1995). Antibodies to interleukin 12 abrogate established experimental colitis in mice. J Exp Med 182: 1281-1290.
21. OECD (2001). Guidelines for the Testing of Chemicals, OECD 420. Acute Oral Toxicity-Fixed Dose Procedure. Organisation for Economic Cooperation and Development: Paris.
22. Oliveira FA, Lima-Junior RC, Cordeiro WM, Vieira-Junior GM, Chaves MH, Almeida FR et al. (2004a). Pentacyclic triterpenoids, alpha,beta-amyrins, suppress the scratching behavior in a mouse model of pruritus. Pharmacol Biochem Behav 78: 719-725.
23. Oliveira FA, Vieira-Junior GM, Chaves MH, Almeida FR, Santos KA, Martins FS et al. (2004b). Gastroprotective effect of the mixture of alpha-and beta-amyrin from Protium heptaphyllum: role of capsaicin-sensitive primary afferent neurons. Planta Med 70: 780-782.
24. Oliveira FA, Chaves MH, Almeida FR, Lima RC Jr, Silva RM, Maia JL, et al. (2005). Protective effect of alpha-and beta-amyrin, a triter-pene mixture from Protium heptaphyllum (Aubl.) March. trunk wood resin, against acetaminophen-induced liver injury in mice. J Ethnopharmacol 98: 103-108.
25. Otuki MF, Ferreira J, Lima FV, Meyre-Silva C, Malheiros A, Muller LA et al. (2005a). Antinociceptive properties of mixture of alpha-amyrin and beta-amyrin triterpenes: evidence for participation of protein kinase C and protein kinase A pathways. J Pharmacol Exp Ther 313: 310-318.
26. Otuki MF, Vieira-Lima F, Malheiros A, Yunes RA, Calixto JB (2005b). Topical antiinflammatory effects of the ether extract from Protium kleinii and alpha-amyrin pentacyclic triterpene. Eur J Pharmacol 507: 253-259.
27. Pham H, Chong B, Vincenti R, Slice LW (2008). Ang II and EGF synergistically induce COX-2 expression via CREB in intestinal epithelial cells. J Cell Physiol 214: 96-109.
28. Recio MC, Giner RM, Manez S, Rios JL (1995). Structural requirements for the anti-inflammatory activity of natural triterpenoids. Planta Med 61: 182-185.
29. Rogler G, Brand K, Vogl D, Page S, Hofmeister R, Andus T et al. (1998). Nuclear factor kappaB is activated in macrophages and epithelial cells of inflamed intestinal mucosa. Gastroenterology 115: 357-369.
30. Rudiger AL, Siani AC, Veiga-Junior VF (2007). The chemistry and pharmacology of the South America genus Protium Burm. f. (Burseraceae). Phcog Rev 1: 93-104.
31. Sakamoto C (1998). Roles of COX-1 and COX-2 in gastrointestinal pathophysiology. J Gastroenterol 33: 618-624.
32. Sandor Z, Deng XM, Khomenko T, Tarnawski AS, Szabo S (2006). Altered angiogenic balance in ulcerative colitis: a key to impaired healing? Biochem Biophys Res Commun 350: 147-150.
33. Sartor RB (2006). Mechanisms of disease: pathogenesis of Crohn's disease and ulcerative colitis. Nat Clin Pract Gastroenterol Hepatol 3: 390-407.
34. Schroer K, Zhu Y, Saunders MA, Deng WG, Xu XM, Meyer-Kirchrath J et al. (2002). Obligatory role of cyclic adenosine monophosphate response element in cyclooxygenase-2 promoter induction and feedback regulation by inflammatory mediators. Circulation 105: 2760-2765.
35. Selve N, Wohrmann T (1992). Intestinal inflammation in TNBS sensitized rats as a model of chronic inflammatory bowel disease. Mediators Inflamm 1: 121-126.
36. Siani AC, Ramos MF, Menezes-de-Lima O Jr, Ribeiro-dos-Santos R, Fernadez-Ferreira E, Soares RO et al. (1999). Evaluation of anti-inflammatory- related activity of essential oils from the leaves and resin of species of Protium. J Ethnopharmacol 66: 57-69.
37. Tolstanova G, Khomenko T, Deng X, Chen L, Tarnawski A, Ahluwalia A et al. (2008). Neutralizing anti-VEGF antibody reduces severity of experimental ulcerative colitis in rats. Direct evidence for the pathogenic role of VEGF. J Pharmacol Exp Ther 328: 749-757.
38. Tsiolakidou G, Koutroubakis IE, Tzardi M, Kouroumalis EA (2008). Increased expression of VEGF and CD146 in patients with inflammatory bowel disease. Dig Liver Dis 40: 673-679.
39. Do Vale AE, David JM, Brandao HN, David JP (2005). A new flavonol glycoside derivative from leaves of Moldenhawera nutans. Z Natur-forsch [C] 60: 45-49.
40. Wallace JL, MacNaughton WK, Morris GP, Beck PL (1989). Inhibition of leukotriene synthesis markedly accelerates healing in a rat model of inflammatory bowel disease. Gastroenterology 96: 29-36.
41. Zhao D (2007). Protein kinase Cdelta-mediated CREB activation regulates ghrelin-induced cyclooxygenase-2 expression and prostaglan-din E2 production in human colonic epithelial cells. J Cell Biochem 102: 1245-1255.